Koninklijke Philips N.v. · EURONEXT:PHIA
Koninklijke Philips — Koninklijke Philips N.V. NY Registry Shares — Q2 2026 Earnings Presentation
25 slides from Koninklijke Philips's earnings presentation, Jul 28, 2026
Slide 1: Second quarter 2026 results
Second quarter 2026 results Roy Jakobs, Chief Executive Officer Charlotte Hanneman, Chief Financial Officer July 28, 2026
Slide 2: Important information
Important information Forward-looking statements and other important information This document and the related oral presentation, including responses to questions following the presentation, contain certain forward-looking statements with respect to the financial condition, results of operations and
Slide 3: Key takeaways
Key takeaways Q2 highlights • Comparable sales grew 4%, with growth across all business segments, led by Personal Health; 4% growth in H1 2026 • Adjusted EBITA margin increased 400 bps to 16.4%, including a ~420 bps US tariff refund benefit, • Excluding the US tariff refund benefit, Adj. EBITA margi
Slide 4: Commercial momentum and a solid order book support acceleration of profitable growth in 2026
Commercial momentum and a solid order book support acceleration of profitable growth in 2026 Comparable equipment order intake growth1 Indexed equipment order book1 development 8% 7% 6% 6% 5% 0% -1% In the quarter Rolling last twelve months Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q2 2025 Q3 2025 Q4
Slide 5: Global hospital demand and consumer sentiment
Global hospital demand and consumer sentiment North America Europe Greater China Rest of world Diagnosis & Strong Strong Centralized procurement Solid Treatment and expansion Connected Care Key drivers • Productivity Productivity and • Localization Infrastructure digitalization investments and • Pat
Slide 6: Diagnosis & Treatment: innovation and strategic partnerships strengthen momentum
Diagnosis & Treatment: innovation and strategic partnerships strengthen momentum Strategic partnerships Recent innovations driving order intake Agreement signed for 14 cath labs in the US With one of the largest nonprofit healthcare organizations, supporting advanced minimally invasive procedures an
Slide 7: Advancing innovation across the portfolio
Advancing innovation across the portfolio Image Guided Therapy Ultrasound Magnetic Resonance Smart IQ for Azurion Elevate Plus 4D MR-RT 3.0T MRI - Titanion Advances coronary image AI-powered imaging and First-of-its-kind multi-contrast Next-generation ultra-high- quality and dose management, automat
Slide 8: Diagnosis & Treatment
Diagnosis & Treatment Financial performance In millions of EUR Q2 Q2 unless otherwise stated 2026 2025 Sales 2,085 2,084 Comparable sales growth 2% -1% Adj. EBITA margin 13.9% 13.5% Excluding the US tariff refund benefit 9.3% Income from operations 252 226 Q2 2026 highlights • High-single-digit grow
Slide 9: Connected Care: Strengthening our position as a strategic partner of choice for healthcare providers
Connected Care: Strengthening our position as a strategic partner of choice for healthcare providers Monitoring Multi-year partnership Region Stockholm’s first region- in the US wide hospital-at-home initiative the consortium was selected through a to standardize monitoring across tender led by Karo
Slide 10: Connected Care
Connected Care Financial performance In millions of EUR Q2 Q2 unless otherwise stated 2026 2025 Sales 1,184 1,272 Comparable sales growth 2% -1% Adj. EBITA margin 17.8% 10.4% Excluding the US tariff refund benefit 11.7% Income from operations 152 67 Q2 2026 highlights • Mid-single-digit growth in Mo
Slide 11: Personal Health: Growth, share gains, and momentum driven by innovation, commercial execution and channel expansion
Personal Health: Growth, share gains, and momentum driven by innovation, commercial execution and channel expansion Broad-based momentum New launch Sonicare platforms Avent products Good Housekeeping 2026 Beauty Awards S800 series Compact Shaver launch in China Winners Powered by the revolutionary T
Slide 12: Personal Health
Personal Health NOTE FROM ZOW: Option A Financial performance In millions of EUR Q2 Q2 unless otherwise stated 2026 2025 Sales 909 862 Comparable sales growth 8% 6% Adj. EBITA margin 23.0% 15.2% Excluding the US tariff refund benefit 18.0% Income from operations 204 122 Q2 2026 highlights • All thre
Slide 13: Continued momentum and disciplined execution despite an uncertain macro-environment
Continued momentum and disciplined execution despite an uncertain macro-environment Q2 2026 vs Q2 2025 In millions of EUR unless otherwise stated Sales Adjusted EBITA Free Cash Flow 4,360 Incl. US tariff refund Excl. US tariff refund 222 717 530 Comparable Sales Growth Adjusted EBITA margin Adjusted
Slide 14: Solid underlying margin performance despite cost inflation and tariff headwinds
Solid underlying margin performance despite cost inflation and tariff headwinds Group Adj. EBITA margin1 Q2 2026 2.0% Excl. US 4.2% Incl. US -3.0% 0.0% tariff refund tariff refund 0.8% 16.4% 12.4% 12.2% Adj. EBITA Volume, business Productivity, Cost inflation FX, other Adj. EBITA US tariff refund Ad
Slide 15: Productivity initiatives delivered EUR 258 million year-to-date; on track for EUR 1.5 billion program
Productivity initiatives delivered EUR 258 million year-to-date; on track to deliver our EUR 1.5 billion program 2026-2028 Productivity initiatives savings To date In millions of EUR unless otherwise stated Q2 2026 Q1 2026 - Q2 2026 • Platform & SKU optimization Cost competitiveness • Lower costs an
Slide 16: 2026 outlook
2026 outlook © Koninklijke Philips N.V.
Slide 17: Philips reiterates 2026 comparable sales growth outlook; raises Adj. EBITA margin and Free Cash Flow outlook
Philips reiterates 2026 comparable sales growth outlook; raises Adj. EBITA margin and Free Cash Flow outlook to reflect US tariff refund Full-year 2026 • All business segments growing within the range: Diagnosis & Treatment at the lower end; Connected Care and Personal Health at the upper end Compar
Slide 18: Restructuring, acquisition-related charges and other items
Restructuring, acquisition-related charges and other items Full-year 2026 Restructuring costs • Cost competitiveness (Project Synchronize) ~60 bps • Lean enabling functions (Simplify to Perform) vs previous outlook of ~80 bps Other items • Mainly related to the Consent Decree, other quality action-r
Slide 19: Latest FX, below the line items and segment Other outlook
Latest FX, below the line items and segment Other outlook Q3 2026 Full year 2026 FX, consolidation and deconsolidation impact on sales1 -1% -3% Diagnosis & Treatment +1% -2% Connected Care (including divestment of Emergency Care2) -7% -9% Personal Health 0% -2% Effective tax rate 24-26% Financial in
Slide 20: Financial appendix
Financial appendix © Koninklijke Philips N.V.
Slide 21: Working capital and inventories
Working capital and inventories Group working capital1 Group inventories In millions of EUR unless otherwise stated as % of last twelve months sales2 In millions of EUR unless otherwise stated as % of last twelve months sales2 11.9% 12.7% 3,500 18.1% 18.3% 2,500 10.8% 17.6% 18.2% 9.5% 9.9% 2,000 2,5
Slide 22: Debt maturity profile and liability management
Debt maturity profile and liability management Long-term debt profile and liability management Debt maturity profile as per June 30, 2026 in billions of EUR unless otherwise stated Long-term debt1 • Total net debt position of EUR 5.7 billion 1.8 Short-term debt2 Un-utilized standby and • Maturities
Slide 23: Net capital expenditures, depreciation and amortization
Net capital expenditures, depreciation and amortization In millions of EUR unless otherwise stated Q2 2026 Q2 2025 Net capital expenditures -154 -156 Depreciation -151 -149 Amortization and impairment: -230 -118 of acquired intangible assets -87 -53 of other intangible assets -143 -64 26 Note: Amoun
Slide 24: Restructuring, acquisition-related charges and other items
Restructuring, acquisition-related charges and other items In millions of EUR unless otherwise stated Q1 2026 Q2 2026 Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2025 Restructuring and acquisition- related charges Diagnosis & Treatment (34) 11 14 15 6 8 43 Connected Care 23 (101) 15 17 33 60 126 Personal Hea
Slide 25: PHILIPS
PHILIPS
Koninklijke Philips N.V. NY Registry Shares — Q2 2026 Earnings Presentation on 6ix